还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

: s" p7 \4 T/ U6 a4 V                               
登录/注册后可看大图

9 C: S) B! j4 j1 X请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

$ n3 _' {. B: }7 v1 M( I0 u$ f可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
! a3 s5 J5 b/ k& z# `

Sub-category:
Molecular Targets

  U0 Q) g0 f3 p! z, g3 o2 m1 X7 `
Category:
* }" Z/ _8 K" Y  [2 \# t8 JTumor Biology


0 O! a5 O3 ], x  GMeeting:
8 q  ^; r2 H( k2011 ASCO Annual Meeting

+ B+ o2 _% J1 e" B2 v/ Z9 O
Session Type and Session Title:
! {3 Y5 c( ?# [5 _  ^Poster Discussion Session, Tumor Biology
+ O9 p  f0 p5 T* h6 H  _
1 W0 r' A& G7 J4 h5 a- V
  V" O5 M8 v& u6 iAbstract No:
6 r9 u$ T* {3 @& e9 x# D2 n10517


# h) h( L7 c3 o1 {9 S5 QCitation:
9 v: \* u+ f2 G6 Z: cJ Clin Oncol 29: 2011 (suppl; abstr 10517)
- C1 Y# m5 W- {- ]  l$ u* f) _/ X! c
$ M: ~  o) T* U3 C; T
Author(s):
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China

$ a- H7 n/ H. h& ?

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
( {2 F2 o. a8 @( e( A
$ t8 ?, ]5 A- GAbstract Disclosures
/ q- p* v: a9 h- C+ F- |+ {- v
! B# e8 X( I$ L- p! a4 C4 nAbstract:
* z# g$ |- k$ ^# z# _2 f( k2 D
/ g. t; C* ^8 S: h1 f" t2 R' a
: ^0 w& B6 }8 G& g  x7 L' \: m7 n7 T+ DBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.

' l+ u$ G. O3 M$ E! w# {$ M: W

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

8 R# Q* U2 i* |6 U% W! s2 {: {没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

% N; D5 ]- r% `7 f3 r. m  [8 i# O3 u化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

( c. k% i/ L7 Q) L" u, m                               
登录/注册后可看大图

: \* ?. H9 o2 ~. T3 U4 K易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

! R' w0 ~  O8 v" Q平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊